

Wei Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1341194/publications.pdf>

Version: 2024-02-01

44
papers

15,139
citations

279798

23
h-index

265206

42
g-index

45
all docs

45
docs citations

45
times ranked

20259
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. <i>Cancer Science</i> , 2022, 113, 756-769.	3.9	29
2	Integrated analysis of the prognostic and oncogenic roles of OPN3 in human cancers. <i>BMC Cancer</i> , 2022, 22, 187.	2.6	6
3	Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes. <i>Frontiers in Oncology</i> , 2022, 12, 714338.	2.8	4
4	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5691.	4.1	11
5	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 186-195.	3.9	7
6	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
7	Uronic acid metabolic process-related gene expression-based signature predicts overall survival of glioma. <i>Bioscience Reports</i> , 2021, 41, .	2.4	0
8	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 617-628.	3.9	7
9	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1707-1718.	2.0	12
10	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12.	6.9	439
11	A potentially effective drug for patients with recurrent glioma: sermorelin. <i>Annals of Translational Medicine</i> , 2021, 9, 406-406.	1.7	1
12	Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. <i>British Journal of Cancer</i> , 2021, 125, 255-264.	6.4	9
13	neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival. <i>BMC Bioinformatics</i> , 2021, 22, 382.	2.6	3
14	Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. <i>Frontiers in Genetics</i> , 2021, 12, 741325.	2.3	0
15	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion. <i>Frontiers in Immunology</i> , 2021, 12, 800928.	4.8	6
16	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. <i>Cancer Medicine</i> , 2020, 9, 1955-1965.	2.8	10
17	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. <i>Scientific Reports</i> , 2020, 10, 16218.	3.3	15
18	A novel methylation signature predicts radiotherapy sensitivity in glioma. <i>Scientific Reports</i> , 2020, 10, 20406.	3.3	5

#	ARTICLE	IF	CITATIONS
19	Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma. <i>Frontiers in Immunology</i> , 2020, 11, 580934.	4.8	17
20	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. <i>Frontiers in Immunology</i> , 2020, 11, 581209.	4.8	26
21	Molecular subtyping reveals immune alterations in <i>IDH</i> wild-type lower-grade diffuse glioma. <i>Journal of Pathology</i> , 2020, 251, 272-283.	4.5	42
22	Classification of diffuse lower-grade glioma based on immunological profiling. <i>Molecular Oncology</i> , 2020, 14, 2081-2095.	4.6	48
23	Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. <i>Cancers</i> , 2020, 12, 3859.	3.7	20
24	<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10263-10273.	2.0	25
25	The Immune Landscape of Cancer. <i>Immunity</i> , 2018, 48, 812-830.e14.	14.3	3,706
26	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , 2018, 23, 255-269.e4.	6.4	204
27	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , 2018, 9, 1190.	6.3	42
28	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. <i>Cell</i> , 2018, 175, 1665-1678.e18.	28.9	250
29	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>Oncolmmunology</i> , 2017, 6, e1328339.	4.6	114
30	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. <i>Oncolmmunology</i> , 2016, 5, e1196310.	4.6	176
31	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	7.2	448
32	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563.	28.9	1,695
33	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	27.0	2,582
34	Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. <i>Acta Neuropathologica</i> , 2015, 130, 587-597.	7.7	68
35	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , 2015, 6, 36643-36651.	1.8	39
36	A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3538-3543.	7.1	93

#	ARTICLE	IF	CITATIONS
37	RNA-seq of 272 gliomas revealed a novel, recurrent <i>PTPRZ1-MET</i> fusion transcript in secondary glioblastomas. <i>Genome Research</i> , 2014, 24, 1765-1773.	5.5	316
38	Multidimensional analysis of gene expression reveals TGFBI1-induced EMT contributes to malignant progression of astrocytomas. <i>Oncotarget</i> , 2014, 5, 12593-12606.	1.8	36
39	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	28.9	3,979
40	Whole-Genome mRNA Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 714-720.	3.9	24
41	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP ⁺ primary glioblastoma. <i>Cancer Letters</i> , 2013, 328, 120-125.	7.2	61
42	Whole-genome microRNA expression profiling identifies a 5 ⁺ microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. <i>Cancer</i> , 2013, 119, 814-824.	4.1	79
43	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. <i>Neuro-Oncology</i> , 2012, 14, 1432-1440.	1.2	163
44	Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China. <i>PLoS ONE</i> , 2012, 7, e30339.	2.5	114